BioHarvest Sciences (BHST) AI Stock Analysis

• Market Cap: $115.76M
• Dividend Yield: N/A
• Average Volume (3M): 78.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 45.88%
• EPS Growth: 43.12%
• Country: US
• Employees: 87
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): -0.14
• Shares Outstanding: 22,654,290
• 10 Day Avg. Volume: 86,360
• 30 Day Avg. Volume: 78,844
• PEG Ratio: 0.55
• Price to Book (P/B): 75.25
• Price to Sales (P/S): 3.97
• P/FCF Ratio: -10.51
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: 5.28
• Enterprise Value/Gross Profit: 8.92
• Enterprise Value/Ebitda: -37.50
• 1Y Price Target: $13.00
• Price Target Upside: 15.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $5.00 ▼(-55.67% Downside)

The score is held down primarily by weak financial performance (ongoing net losses, negative operating/free cash flow, and elevated leverage) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improving gross margins, and guidance pointing toward adjusted EBITDA breakeven, but valuation remains constrained by unprofitability and no dividend.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market reach and product adoption, supporting long-term business sustainability.

Strategic Partnership

This partnership enhances product offerings and leverages innovative technology, potentially transforming market dynamics in the nutraceutical sector.

Improved Liquidity

Improved liquidity strengthens financial stability, providing flexibility for strategic investments and operational resilience.

Negative Factors

High Leverage

Significant leverage poses financial risk, limiting flexibility and increasing vulnerability to economic fluctuations.

Negative Profit Margins

Ongoing profitability issues highlight operational inefficiencies, which could hinder long-term growth and competitiveness.

Increased Operating Expenses

Rising expenses without proportional revenue growth can strain financial resources, impacting profitability and cash flow.

BioHarvest Sciences Business Overview & Revenue Model

Company Description

BioHarvest Sciences (BHST) is a biotechnology company specializing in the development and commercialization of innovative plant-based products for the health and wellness sectors. The company leverages its proprietary technology to produce high-quality, bioavailable compounds from various plants, targeting markets such as dietary supplements, nutraceuticals, and functional foods. With a focus on sustainability and scalability, BioHarvest aims to meet the growing consumer demand for natural health solutions.

How the Company Makes Money

BioHarvest Sciences generates revenue primarily through the sale of its proprietary plant-based products, including dietary supplements and nutraceuticals. The company has established key partnerships with manufacturers and distributors in the health and wellness industry, allowing it to reach a broader customer base. Additionally, BioHarvest may engage in licensing agreements for its technology and formulations, creating another revenue stream. The company is also exploring opportunities in the functional food market, potentially expanding its product offerings and increasing overall revenue.

BioHarvest Sciences Financial Statement Overview

Summary

BioHarvest Sciences shows revenue growth and some cash flow improvement, but struggles with profitability and financial stability. High leverage and negative returns on equity highlight potential risks.

Income Statement

BioHarvest Sciences shows a positive revenue growth rate of 8.38% in the TTM, indicating an upward trend in sales. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively healthy at 59.21%, suggesting efficient production, but overall profitability remains a concern due to high operating expenses.

Balance Sheet

The company has a high debt-to-equity ratio of 2.57, indicating significant leverage, which poses a financial risk. The return on equity is negative, reflecting ongoing losses and a weak ability to generate returns for shareholders. The equity ratio is low, suggesting limited financial stability and a heavy reliance on debt financing.

Cash Flow

BioHarvest Sciences has a positive free cash flow growth rate of 2.94%, showing improvement in cash generation. However, the operating cash flow is negative, and the operating cash flow to net income ratio is below 1, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is above 1, suggesting some efficiency in managing cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.72M	25.19M	12.67M	5.50M	2.10M	396.00K
Gross Profit	19.37M	13.94M	5.63M	1.22M	670.00K	138.00K
EBITDA	-4.61M	-9.72M	-9.76M	-9.13M	-8.64M	-5.77M
Net Income	-11.89M	-12.91M	-12.56M	-11.24M	-9.83M	-6.58M
Balance Sheet
Total Assets	35.19M	25.00M	15.00M	9.39M	10.21M	5.30M
Cash, Cash Equivalents and Short-Term Investments	10.97M	2.39M	5.36M	1.74M	4.12M	1.78M
Total Debt	19.84M	13.82M	22.34M	10.56M	2.66M	2.71M
Total Liabilities	27.45M	23.67M	29.86M	15.32M	7.35M	7.60M
Stockholders Equity	7.74M	1.33M	-14.85M	-5.93M	2.85M	-2.29M
Cash Flow
Free Cash Flow	-10.07M	-9.52M	-10.00M	-10.50M	-8.43M	-4.05M
Operating Cash Flow	-8.00M	-6.68M	-8.52M	-9.24M	-6.79M	-3.88M
Investing Cash Flow	-2.07M	-3.03M	-1.47M	-1.26M	-1.64M	-173.00K
Financing Cash Flow	18.49M	6.78M	13.56M	8.14M	10.77M	4.93M

BioHarvest Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHST, the sentiment is Negative. The current price of 11.28 is above the 20-day moving average (MA) of 5.34, above the 50-day MA of 6.53, and above the 200-day MA of 7.47, indicating a bearish trend. The MACD of -0.38 indicates Negative momentum. The RSI at 38.78 is Neutral, neither overbought nor oversold. The STOCH value of 36.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BHST.

BioHarvest Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IH	67 Neutral	$99.64M	7.10	11.71%	3.93%	-8.09%	-15.28%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
PRE	51 Neutral	$236.27M	-4.59	-23.93%	―	159.45%	8.59%
HURA	46 Neutral	$45.81M	-1.16	-418.06%	―	―	99.21%
BHST	45 Neutral	$115.76M	-7.46	-200.22%	―	45.88%	43.12%
AGEN	45 Neutral	$127.53M	-1.76	―	―	-33.41%	81.19%
SGMO	45 Neutral	$151.49M	-1.02	-480.02%	―	-37.13%	40.47%

BioHarvest Sciences Corporate Events

BioHarvest Sciences Reports Strong Financial Position in Q3 2025

BioHarvest Sciences Inc. has released its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The financial report highlights a significant increase in cash and cash equivalents from $2,390,000 at the end of 2024 to $10,966,000 as of September 30, 2025, indicating improved liquidity. This financial performance reflects the company’s ongoing efforts to strengthen its financial position, which could enhance its competitive edge in the biotechnology sector.

The most recent analyst rating on (BHST) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.

BioHarvest Sciences Partners with Saffron Tech for Saffron Compound Development

On October 30, 2025, BioHarvest Sciences announced a strategic CDMO agreement with Saffron Tech Ltd., aimed at developing and commercializing saffron-derived botanical compounds. This collaboration leverages BioHarvest’s Botanical Synthesis platform and Saffron Tech’s advanced cultivation methods to produce saffron compounds more sustainably and efficiently. The agreement grants Saffron Tech a 75% ownership of the developed compositions, while BioHarvest retains 25%. This partnership is expected to revolutionize saffron production by transitioning from traditional field-based cultivation to a controlled, cell-based process, addressing global supply challenges and expanding BioHarvest’s product offerings in the nutraceutical market.

The most recent analyst rating on (BHST) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.

BioHarvest Sciences Partners with Saffron Tech to Transform Saffron Production

On October 30, 2025, BioHarvest Sciences announced a strategic partnership with Saffron Tech to develop and commercialize saffron-derived botanical compounds using BioHarvest’s Botanical Synthesis platform. This collaboration aims to revolutionize saffron production by enabling consistent, scalable, and cost-effective production, addressing the challenges of traditional saffron cultivation. The partnership will allow BioHarvest to leverage its technology for large-scale manufacturing and marketing of saffron-based nutraceutical products. Additionally, BioHarvest shared its preliminary third-quarter 2025 results, with expected revenue of approximately $9.1 million and provided guidance for the fourth quarter, highlighting growth in its VINIA® business and CDMO services.

The most recent analyst rating on (BHST) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.